



Medicines & Healthcare products Regulatory Agency

MHRA Central Freedom of
Information Team
10 South Colonnade
Canary Wharf
London
E14 4PU

foi.request@mhra.gov.uk

[MHRA Website](https://www.mhra.gov.uk)

Our Ref: **FOI2025/00099**

4 March 2025

Dear [REDACTED]

Thank you for your Freedom of Information (Fol) request received on 4 February. You wrote:

We understand that the first UK reports of a CVST following vaccination using the AstraZeneca vaccine were received by the MHRA on the 3, 11 and 18 of February 2021. Please confirm on what date the MHRA received the first report and/or was first notified of a cerebral venous sinus thrombosis "CVST" following vaccination using the AstraZeneca vaccine. Please provide all related correspondence in regard to this report, and any additional reports during February 2021.

MHRA Response

We confirm that we hold the information you have requested.

On 3, 11 and 18 February 2021, the MHRA identified 3 Yellow Card reports of thrombotic events occurring with thrombocytopenia associated with the AstraZeneca (Vaxzevria) vaccine. We believe these are the reports you are referring to in your request. There were no additional reports of thrombotic events occurring with thrombocytopenia associated with the AstraZeneca (Vaxzevria) vaccine in February 2021.

We are unable to provide you with some of the information requested as it constitutes personal data of someone other than yourself and as such, it is being withheld in accordance with section 40(2) of the Freedom of Information Act.

Section 40(2) exempts information in response to a request if it is personal data belonging to an individual other than the requester and it satisfies one of the conditions listed in the legislation. We do not consider that disclosing this information is necessary or justified in order to satisfy your information request and the requirements of the Fol Act. In relation to this request, we consider that there is no strong legitimate interest that would override the prejudice to the rights and freedoms of the data subject.

Personal data are subject to UK General Data Protection Regulation (UK GDPR) and the Data Protection Act 2018

If you have any queries about this letter, please contact us quoting the reference number above.

Yours sincerely,

MHRA Central Freedom of Information Team
Medicines & Healthcare products Regulatory Agency

Your right to complain under the Freedom of Information Act

If you are not happy with this response you may request an internal review by e-mailing foi.request@mhra.gov.uk or by writing to: MHRA Central Freedom of Information Team, 10 South, Colonnade, Canary Wharf, London, E14 4PU

Any request for an internal review must be received by us within 40 working days of the date of this letter. Please note we are not obliged to provide a review if it is requested after more than 40 working days.

If you are not content with the outcome of the internal review, you may apply directly to the Information Commissioner's Office for a decision. Generally, the Commissioner cannot make a decision unless you have exhausted our own complaints procedure. The Information Commissioner can be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

Website: [ICO FOI and EIR complaints](#) or telephone 0303 123 1113.

Re-use of our information

The MHRA information supplied in response to your request is subject to Crown copyright. Information created by the MHRA which is disclosed under the Freedom of Information Act is made available for re-use under the Open Government Licence (OGL) v3.0, except where this is otherwise stated. There are some restrictions on re-use under the OGL and these can be viewed here:

<https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>